Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01079130 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Different Doses of Indacaterol
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 511
- Enrollment target
NCT01079130: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT01079130 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 511 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01079130, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 511 participants
- Enrollment target
Study Summary
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol
Primary Outcome
Spirometry was conducted according to internationally accepted standards. The trough FEV1 was defined as the average of the FEV1 measurements taken at 23 hours 10 minutes and 23 hours 45 minutes post dose. The mixed model used baseline FEV1 and FEV1 prior to and 30 minutes post inhalation of albuterol as covariates.
Interventions
- DRUG Salmeterol
- DRUG Indacaterol
- DRUG Placebo to Indacaterol
- DRUG Placebo to Salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2010-02 |
| Phase | Phase 3 |
What the finished NCT01079130 record still lists
NCT01079130 is an interventional study that assigns participants to a tested intervention. The registered 511 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 4 interventions - of which Salmeterol is the first listed.
NCT01079130 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01079130 about?
NCT01079130 is a clinical study titled "Efficacy and Safety of Different Doses of Indacaterol". This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol
What is the current status of trial NCT01079130?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 511 participants. The study started on 2010-02.
What interventions are being tested in trial NCT01079130?
The interventions under investigation include: Salmeterol (DRUG), Indacaterol (DRUG), Placebo to Indacaterol (DRUG), Placebo to Salmeterol (DRUG).
Who is sponsoring clinical trial NCT01079130?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01079130's enrollment target sits among peer trials
511 728th of 2000 higher than 1,272 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia